<DOC>
	<DOCNO>NCT02567773</DOCNO>
	<brief_summary>GSK2881078 selective androgen receptor modulator ( SARM ) evaluate effect muscle growth strength subject muscle waste improve physical function . Part A study evaluate safety , efficacy pharmacokinetics GSK2881078 healthy , old men post-menopausal woman take daily dose 28 day follow total 70 day . Part B study characterize effect Cytochrome P450 3A4 ( CYP3A4 ) inhibition GSK2881078 pharmacokinetics . Part B conduct safe efficacious dose identify Part A . Part A include healthy old male post-menopausal female ; randomize approximately 60 subject ( 15 per cohort [ 4 cohort ] ) complete approximately 48 ( 12 per cohort ) . Part B enroll one cohort approximately 15 healthy male subject complete approximately 12 . The study duration approximately 115 day Part A 122 day Part B .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic ( PK ) , Pharmacodynamic Study GSK2881078 Study Evaluate Effect CYP3A4 Inhibition PK GSK2881078</brief_title>
	<detailed_description />
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Age : Part A : Between 50 75 year age inclusive , time signing informed consent form . Part B : Between 18 60 year age inclusive , time signing informed consent form . Healthy determine investigator . Subjects hypertension , hyperlipidemia hypothyroidism , well control stable single medication , may also include . Subject value Hemoglobin ( Hgb ) must within normal range ( plus minus 10 % ) . Estimated glomerular filtration rate ( GFR ) &gt; =60 milliliter ( mL ) /minute ( min ) /1.73 square meter ( m^2 ) . Body Mass Index ( BMI ) within range 19 32 kilogram ( kg ) /m^2 ( inclusive ) . Sex : Part A : Male Female ; Part B : Male Males : Male subject female partner child bear potential must agree use condom time first dose study medication final followup visit . Females : A female subject eligible participate postmenopausal . Alanine transaminase ( ALT ) bilirubin &gt; 1.1x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.1xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease include fatty liver , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Corrected QT interval ( QTc ) &gt; 450 msec . Heart rate : &lt; 40 &gt; 100 beat per minute , PR Interval : &lt; 120 &gt; 210 millisecond ( msec ) , QRS duration : &lt; 70 &gt; 120 msec . Subjects history time past coronary artery disease , congestive heart failure , angina , myocardial infarction , cardiac surgery , valvular heart disease , clinically significant arrhythmia , dyspnea , pulmonary edema , stroke , transient ischemic attack . Subjects history clinically significant endocrine , gastrointestinal , hepatic , cardiovascular , neurological , haematological , immunological , renal , respiratory , genitourinary abnormality disease . Subjects history malignancy complete remission least 5 year 1 year nonmelanoma skin carcinoma . Male subject family history early onset ( 55 year age young ) prostate cancer 2 direct family member prostate cancer . Unable refrain prescription nonprescription drug describe protocol . History regular alcohol consumption within 6 month study . History drug alcohol abuse within 5 year prior Screening Period . Unable refrain consumption ( whole fruit juice ) seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid . Regular , strenuous exercise weightlift &gt; 2 time per week least 2 week prior screen visit intent start new exercise routine study . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof . Metal implant ( contraindicate MRI disrupt DXA imaging ) . These include intraorbital metal fragment . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . For potent immunosuppressive agent , subject presence hepatitis B core antibody ( HBcAb ) also exclude . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Subjects previously receive GSK2881078 allow participate trial , timeline restriction . Exposure four new chemical entity within 12 month prior first dose day . Prostate Specific Antigen ( PSA ) &gt; 4.0 nanogram ( ng ) /mL . Highdensity lipoprotein cholesterol ( HDLC ) &lt; 35 milligram ( mg ) /deciliter ( dL ) . Thyroid stimulate hormone ( TSH ) &gt; 10 mIU/L , test may repeat thyroid panel discuss Medical Monitor . Testosterone &lt; 0.9 low limit normal range ( LLNR ) 10 % , test may repeat , free testosterone determine also &lt; 0.9 LLNR .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Itraconazole</keyword>
	<keyword>GSK2881078</keyword>
	<keyword>CYP3A4</keyword>
	<keyword>Selective Androgen Receptor Modulator</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Tolerability</keyword>
</DOC>